Overview of Q3 2025 Results Compugen has released its third-quarter 2025 results, underscoring continued momentum in its oncology pipeline and the strategic progress of key clinical programs. The company reaffirmed its commitment to advancing targeted cancer therapies, with a particular focus on COM701 data presented at ESMO 2025 and the ongoing expansion of the MAIA-ovarian…